Can a Two-Drug punch restore sensitivity in Hard-to-Treat prostate cancer?
NCT ID NCT05037500
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether adding decitabine/cedazuridine to enzalutamide could help men with metastatic castration-resistant prostate cancer whose cancer had stopped responding to enzalutamide alone. Only 8 men were enrolled before the study was terminated. The goal was to find a safe dose and see if the combination could reverse drug resistance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Decitabine and cedazuridine (ASTX727, Inqovi) combined with enzalutamide (Xtandi)
- What this could lead to
- If it works, this combination could help men with advanced prostate cancer whose disease has stopped responding to enzalutamide alone.
- What could go wrong
- This was a very early, small Phase 1b trial that was terminated, so results are limited. The combination may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Double-Dose precision: new combo radiation aims to shrink prostate tumors faster
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?